Ablynx Stock

Stocks

18-10-15	AstraZeneca : Novo Nordisk hires AstraZeneca executive to revive struggling biopharma unit	RE
18-04-27	Sanofi : sees new acquisitions and drugs reviving growth	RE
18-04-17	Blackstone LP : Sanofi in talks to sell generics arm to Advent for 1.9 billion euros	RE
18-03-29	Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	RE
18-03-29	Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	RE
18-03-28	Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid	RE
18-03-22	Ablynx : Drugmaker Novo Nordisk looks to former oil boss to energise M&A	RE
18-02-07	Ablynx : Sanofi's return to profit growth this year slower than hoped	RE
18-01-29	Ablynx : Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom	RE
18-01-29	Ablynx : Chipmakers, Sanofi deal dominate European share trading	RE
18-01-29	Ablynx : Novo Nordisk remains on hunt for biopharma deals	RE
18-01-22	Ablynx : Biotech M&A takes off as Sanofi and Celgene spend $20 billion	RE
18-01-22	Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	RE

20-11-19	Immunicum : and DCprime Combine Forces to Establish Leader in Cell-Based Cancer Immunotherapies	AQ
18-06-19	Ablynx : SANOFI COMPLETES ITS ACQUITISION OF ABLYNX FOLLOWING THE EXPIRATION OF THE SQUEEZE-OUT PROCEDURE	GL
18-05-28	Ablynx : PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")	GL
18-05-28	Ablynx : PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")	GL
18-05-25	Ablynx : NOTICE IN RELATION TO THE CONVERTIBLE BONDS DUE MAY 2020	GL

18-06-19	SANOFI : a finalisé l'acquisition d'Ablynx
18-05-14	Les marchés européens marquent une pause, scrutent la politique italienne
18-05-14	Sanofi : A suivre aujourd'hui
18-05-14	SANOFI : détient 95,60% des actions d'ABLYNX
18-04-27	Sanofi : Les taux de change freinent les résultats, T2 terne en vue

Manager	Title	Age	Since
Geert Deschamps CEO	Chief Executive Officer	-	2025-03-06

Director	Title	Age	Since
Kristine de Sutter BRD	Director/Board Member	-	2019-03-31
Pieter Oldenziel BRD	Director/Board Member	-	2018-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABLYNX	-.--%	+0.09%	-	-	0
LONZA GROUP AG	+0.11%	+2.71%	+0.33%	+28.59%	46.18B
IQVIA HOLDINGS INC.	-1.12%	+1.78%	+40.07%	+27.26%	44.35B
REVOLUTION MEDICINES, INC.	-3.04%	-6.29%	+322.27%	+517.36%	42.21B
BEONE MEDICINES AG	-0.74%	+1.25%	+2.32%	+67.94%	40.19B
CELLTRION, INC.	-0.50%	+0.67%	+11.79%	+40.51%	29.83B
MEDPACE HOLDINGS, INC.	-0.46%	+4.22%	+21.99%	+124.21%	17.17B
ASCENDIS PHARMA A/S	-0.97%	-10.17%	-	-	15.7B
EUROFINS SCIENTIFIC SE	-0.57%	+8.12%	+22.15%	+38.93%	15.32B
TEMPUS AI, INC.	-3.14%	+31.91%	-10.60%	-	14.5B
Average	-0.89%	+4.59%	+51.29%	+120.69%	29.49B
Weighted average by Cap.	-1.03%	+2.74%	+65.68%	+131.93%